Clinical Trial Results:
Stem cells in Rapidly Evolving Active Multiple Sclerosis (STREAMS)
Summary
|
|
EudraCT number |
2012-002357-35 |
Trial protocol |
GB |
Global end of trial date |
31 Jul 2019
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
29 Dec 2019
|
First version publication date |
29 Dec 2019
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
CRO1959
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT01606215 | ||
WHO universal trial number (UTN) |
- | ||
Other trial identifiers |
Clinicaltrials.gov: NCT01606215 | ||
Sponsors
|
|||
Sponsor organisation name |
Imperial College London
|
||
Sponsor organisation address |
160 Du Cane Road Burlington Danes Building Hammersmith Campus , London, United Kingdom, W12 0NN
|
||
Public contact |
Dr Paolo Muraro, Imperial College London, +44 02075946670, p.muraro@imperial.ac.uk
|
||
Scientific contact |
Dr Paolo Muraro, Imperial College London, +44 02075946670, p.muraro@imperial.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Interim
|
||
Date of interim/final analysis |
16 Sep 2019
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
25 May 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
31 Jul 2019
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
There are two co-primary objectives.
The first is to assess the safety of intravenous therapy with autologous (derived from the individuals themselves) MSCs in MS patients. The safety of MSCs infusion will be evaluated including frequency, timing and severity of any adverse events in both MSCs and placebo treatment groups.
The second is to evaluate the activity of autologous MSCs in MS patients, quantified by the reduction in the number of new contrast-enhancing lesions on MRI scans over 24 weeks, the latter suggesting new inflammation.
|
||
Protection of trial subjects |
1. For procedures such as lumbar punctures, skin biopsy and the bone marrow harvest, local anaesthetic was used to minimise pain during the procedure
2. Patients could voluntarily withdraw at any time from the study and follow-up assessments.
3. Unblinding could be requested if the clinical situation warranted it on patient safety grounds
4. The patient’s participation in the study could also be discontinued at any time at the discretion of the investigator - justifiable reasons include dSuspected Unexpected Serious Adverse Reactions (SUSAR) or deterioration in the disease activity requiring immunomodulatory treatment
|
||
Background therapy |
N/A - the patients were not on any other treatment during the trial. | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
26 Mar 2013
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 21
|
||
Worldwide total number of subjects |
21
|
||
EEA total number of subjects |
21
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
21
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||
Recruitment details |
Patients from the UK were recruited at Imperial College Healthcare Trust between 23 March 2013 and 26 June 2015 | ||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||
Screening details |
A total of 21 patients with multiple sclerosis were screened and randomised but only 13 patients completed the trial. Details: 1 patient withdrew consent after screening, 1 patient's MRI did not meet criteria after review and 6 patients failed to meet the required MSC dose after expansion | ||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||
Period 1 title |
Randomisation
|
||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||
Roles blinded |
Investigator, Subject | ||||||||||||||||||||||||
Blinding implementation details |
All subjects were randomised after verifying that they are eligible. Randomisation was carried out within a web-based system, made available to authorised researchers, by the Clinical Research Organisation (CRO) in charge.
The stem cell laboratory was made aware of the allocation (so that the order of the infusion) - both infusions were made to identical volumes and appearance - was known but the patients, investigators and data analysts were blinded to treatment allocation.
|
||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
Early MSC-treated | ||||||||||||||||||||||||
Arm description |
Patients receiving 1-2 x106cells/kg MSCs in the first infusion | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
Mesenchymal Stem cells
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||
Dosage and administration details |
1-2 x106 million MSC cells/kg suspended in 5% HAS/10% DMSO
|
||||||||||||||||||||||||
Arm title
|
Placebo | ||||||||||||||||||||||||
Arm description |
placebo Drug Product comprising 5% HAS/10% DMSO is prepared - only lacks the MSCs that are present in the active arm | ||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||
Investigational medicinal product name |
placebo
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||
Dosage and administration details |
equal volume of 5% HAS/10% DMSO
|
||||||||||||||||||||||||
|
|||||||||||||||||||||||||
Period 2
|
|||||||||||||||||||||||||
Period 2 title |
Crossover
|
||||||||||||||||||||||||
Is this the baseline period? |
No | ||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||
Roles blinded |
Subject, Investigator | ||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||
Arm title
|
MSCs after placebo | ||||||||||||||||||||||||
Arm description |
Patients receiving 1-2 x106cells/kg MSCs in the first infusion | ||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||
Investigational medicinal product name |
Mesenchymal Stem cells
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||
Dosage and administration details |
1-2 x106 million MSC cells/kg suspended in 5% HAS/10% DMSO
|
||||||||||||||||||||||||
Arm title
|
Placebo after treatment | ||||||||||||||||||||||||
Arm description |
placebo Drug Product comprising 5% HAS/10% DMSO is prepared - only lacks the MSCs that are present in the active arm | ||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||
Investigational medicinal product name |
placebo
|
||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||
Pharmaceutical forms |
Suspension for injection
|
||||||||||||||||||||||||
Routes of administration |
Intravenous use
|
||||||||||||||||||||||||
Dosage and administration details |
equal volume of 5% HAS/10% DMSO
|
||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Randomisation
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis sets
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
early msc treated completed
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Sub-group analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
early msc treated period 1 pts who completed treatment
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set title |
delayed MSC group
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set type |
Sub-group analysis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Subject analysis set description |
pts receiving MSCs at Week 24 having received placebo at Week 0
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Early MSC-treated
|
||
Reporting group description |
Patients receiving 1-2 x106cells/kg MSCs in the first infusion | ||
Reporting group title |
Placebo
|
||
Reporting group description |
placebo Drug Product comprising 5% HAS/10% DMSO is prepared - only lacks the MSCs that are present in the active arm | ||
Reporting group title |
MSCs after placebo
|
||
Reporting group description |
Patients receiving 1-2 x106cells/kg MSCs in the first infusion | ||
Reporting group title |
Placebo after treatment
|
||
Reporting group description |
placebo Drug Product comprising 5% HAS/10% DMSO is prepared - only lacks the MSCs that are present in the active arm | ||
Subject analysis set title |
early msc treated completed
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
early msc treated period 1 pts who completed treatment
|
||
Subject analysis set title |
delayed MSC group
|
||
Subject analysis set type |
Sub-group analysis | ||
Subject analysis set description |
pts receiving MSCs at Week 24 having received placebo at Week 0
|
|
|||||||||||||
End point title |
number of adverse events [1] [2] | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
24 week period in each half of the trial
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: numbers too small [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: numbers too small |
|||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
number of relapses in first period | ||||||||||||
End point description |
total number of relapses in MSC treated periods vs sham periods
|
||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
12 months
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
total number of relapses in second period | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
6 months
|
||||||||||||
|
|||||||||||||
No statistical analyses for this end point |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
12 months
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
CTCAE | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
4
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
msc treated
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
13 patients receiving MSCs either at Week 0 or Week 24 11 total AEs in 7 pts | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
placebo group
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
13 patients given sham infusion either at week 0 or at week 24 4 adverse events in total in 3 patients | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
13 Sep 2013 |
requesting additional blood samples and inserting an additional mantoux test |
||
03 Jan 2014 |
1.The inclusion criterion “Disease duration 2-10 years from diagnosis” was changed to “Disease duration 0-10 years from diagnosis”. T
2. The inclusion criterion “EDSS 3.0 - 6.5 at screening evaluation” was changed to “EDSS 2.0 - 6.5 at screening evaluation”
3.inclusion criterion “≥1GEL on MRI within 3 months prior to harvesting” was changed to “≥1GEL on MRI within 6 months prior to harvesting”
|
||
02 Apr 2014 |
to allow a dose range of 1-2 x106 cells/kg rather than stipulate 2 x 106 cells/kg |
||
14 Jan 2015 |
to allow second phase of recruitment into streams |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
small study but double blind and randomised |